The Extent of Lung Parenchyma Resection Significantly Impacts Long-Term Quality of Life in Patients With Non-Small Cell Lung Cancer

CHEST Journal ◽  
2009 ◽  
Vol 135 (2) ◽  
pp. 322-329 ◽  
Author(s):  
Tobias Schulte ◽  
Bodo Schniewind ◽  
Peter Dohrmann ◽  
Thomas Küchler ◽  
Roland Kurdow
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lung Parenchyma ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Quality of Life Supersedes the Classic Prognosticators for Long-Term Survival in Locally Advanced Non–Small-Cell Lung Cancer: An Analysis of RTOG 9801

2009 ◽  
Vol 27 (34) ◽  
pp. 5816-5822 ◽  
Author(s):  
Benjamin Movsas ◽  
Jennifer Moughan ◽  
Linda Sarna ◽  
Corey Langer ◽  
Maria Werner-Wasik ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Prognostic Factors ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung

Purpose To determine the added value of quality of life (QOL) as a prognostic factor for overall survival (OS) in patients with locally advanced non–small-cell lung cancer (NSCLC) treated on Radiation Therapy Oncology Group RTOG-9801. Patients and Methods Two hundred forty-three patients with stage II/IIIAB NSCLC received induction paclitaxel and carboplatin (PC) and then concurrent weekly PC and hyperfractionated radiation (to 69.6 Gy). Patients were randomly assigned to amifostine (AM) or no AM during chemoradiotherapy. The following pretreatment factors were analyzed as prognostic factors for OS: Karnofsky performance status, stage, sex, age, race, marital status, histology, tumor location, hemoglobin, tobacco use, treatment arm (AM v no AM) and QOL scores (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 [QLQ-C30] and Lung Cancer 13 [LC-13]). A multivariate (MVA) Cox proportional hazards model was performed using a backwards selection process. Results Of the 239 analyzable patients, 91% had a baseline global QOL score. Median follow-up time was 59 months for patients still alive and 17 months for all patients. Median baseline QLQ-C30 global QOL score was 66.7 on both treatment arms. Whether the global QOL score was treated as a dichotomized variable (based on the median score) or a continuous variable, all other variables fell out of the MVA for OS. Patients with a global QOL score less than 66.7 had an approximately 70% higher rate of death than patients with scores ≥ 66.7 (P = .004). A 10-point higher baseline global QOL score corresponded to a decrease in the hazard of death by approximately 10% (P = .004). The other independent QOL predictors for OS were the QLQ-C30 physical functioning (P = .011) and LC-13 dyspnea scores (P = .012). Conclusion In this analysis, baseline global QOL score replaced known prognostic factors as the sole predictor of long-term OS for patients with locally advanced NSCLC.

Association of Depression and Anxiety on Quality of Life, Treatment Adherence, and Prognosis in Patients with Advanced Non-small Cell Lung Cancer

2012 ◽  
Vol 20 (6) ◽  
pp. 1941-1948 ◽  
Author(s):  
Óscar Arrieta ◽  
Laura P. Angulo ◽  
Carolina Núñez-Valencia ◽  
Yuzmiren Dorantes-Gallareta ◽  
Eleazar O. Macedo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Treatment Adherence ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Depression And Anxiety ◽  
Small Cell Lung

Quality Trials and Quality of Life in Non–Small-Cell Lung Cancer

2003 ◽  
Vol 21 (16) ◽  
pp. 3007-3008 ◽  
Author(s):  
Peter Harper ◽  
Tim Plunkett ◽  
David Khayat
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document